Market Place
Sourcing Support
All News #Library
Biotech
Entera Bio Unveils 2025 Financials, Business Updates
27 Mar 2026 //
GLOBENEWSWIRE
OPKO, Entera Advance Oral Long-Acting PTH for Hypoparathyroidism
04 Feb 2026 //
GLOBENEWSWIRE
Entera Bio Reveals Q3 2025 Financials & Business Developments
14 Nov 2025 //
GLOBENEWSWIRE
Entera Bio Unveils Strong Results In EB613 Phase 2 Trial
23 Oct 2025 //
GLOBENEWSWIRE
Entera Bio To Unveil Phase 2 EB613 Trial Data At 2025 NAMS
16 Oct 2025 //
GLOBENEWSWIRE
Entera Bio Reveals EB613`s Positive Impact on Osteoporosis
08 Sep 2025 //
GLOBENEWSWIRE
Entera Bio to Present Data From 3 Oral Peptide Programs in Sept
28 Aug 2025 //
GLOBENEWSWIRE
Entera Bio Reveals Q2 2025 Financial Results and Updates
08 Aug 2025 //
GLOBENEWSWIRE
FDA Approves BMD as Primary Endpoint in EB613 Ph3 Study
28 Jul 2025 //
GLOBENEWSWIRE
Entera Bio`s EB613 Shows Early Impact on Bone in Post-Menopausal
15 Apr 2025 //
GLOBENEWSWIRE
OPKO & Entera to Advance First Oral GLP-1/Glucagon Drug
19 Mar 2025 //
BIOSPACE
Entera Bio Reports Q3 2024 Financial Results & Business Updates
08 Nov 2024 //
GLOBENEWSWIRE
Entera`s Oral PTH Hypoparathyroidism Candidate EB612 Phase 1 Data
03 Jun 2024 //
GLOBENEWSWIRE
Entera Bio Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide
20 Mar 2024 //
GLOBENEWSWIRE
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
07 Jun 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.